Kathryn E. Falberg, Director at Aimmune Therapeutics, Inc. (AIMT), bought 30,000 shares at $32.00 ($960K) on 2018-02-26, disclosed to the SEC on 2018-02-26.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| TTD | SELL | 2024-03-12 | $16.9M | — | Filing → |
| NUVB | BUY | 2022-12-05 | $789K | — | Filing → |
| TTD | SELL | 2021-11-23 | $32.5M | — | Filing → |